8月19日，先健科技(01302)盘中上涨5.0%，截至13:06，报2.31元/股，成交8188.02万元。 先健科技专注于心脑血管和外周血管介入医疗器械的研发、生产及全球化发展，产品在国内市场占据领 先地位，并拓展至全球120多个国家和地区。公司已获得2,426项高质量专利，15款产品通过NMPA创新 医疗器械审查程序，持续推动技术突破与国际化发展。 8月29日，先健科技将披露2025财年中报。 本文源自：金融界 作者：行情君 截至2024年年报，先健科技营业总收入13.04亿元、净利润2.22亿元。 ...

LifeTech Scientific Corporation 先健科技公司 （在開曼群島註冊成立的有限公司） （股份代號：1302） 董事會會議通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 1） 考慮及批准本公司及其附屬公司（「本集團」）截至二零二五年六月三十日止六個 月的未經審核中期業績，並批准將於香港交易及結算所有限公司及本公司網站 刊登的本集團的未經審核中期業績公佈； 2） 考慮派發中期股息（如有）； 3） 考慮暫停辦理本公司股份過戶登記手續（倘有需要）；及 4） 處理任何其他事項（如有）。 先健科技公司（「本公司」）董事會（「董事會」）謹此公佈，將訂於二零二五年八月 二十九日（星期五）舉行董事會會議，以商討下列事項： 承董事會命 先健科技公司 執行董事、主席兼首席執行官 謝粵輝 香港，二零二五年八月十一日 於本公佈日期，董事會成員包括本公司執行董事謝粵輝先生、劉劍雄先生及阮杏梅女士；本公司非 執行董事姜峰先生；及本公司獨立非執行董事 ...

Market Overview - The A-share market showed strong performance with the Shanghai Composite Index steadily rising, while the Hong Kong stock market experienced a narrow fluctuation, closing up by 0.03% [1] - Concerns in the market are heightened due to the U.S. President Trump's shortened ultimatum for sanctions against Russia, now set at 10 days, with potential impacts on India and other countries [1] - The U.S. is also set to impose significant tariffs on semiconductor chips and pharmaceuticals, with drug tariffs reaching as high as 250% [1] Company Developments - Jingtai Technology announced a pipeline cooperation agreement with DoveTree worth approximately HKD 470 billion (USD 59.9 billion), leading to a stock surge of over 12% [2] - A-share company Weixin New Materials faced regulatory scrutiny after a stock price surge related to the "embodied intelligent robot" concept and control change expectations [2] - The Shanghai government released a plan for the development of the embodied intelligence industry, aiming for breakthroughs in core algorithms and technologies by 2027 [2] Industry Trends - The 2025 World Robot Conference is set to showcase over 100 new products, nearly double from last year, indicating a growing interest in robotics [3] - The U.S. student loan delinquency rate has reached 12.9%, the highest in 21 years, which may influence Federal Reserve decisions on interest rates [3] - The steel and paper industries are experiencing positive momentum, with companies like Maanshan Steel and Nine Dragons Paper seeing significant stock price increases [3] Defense Sector Insights - The military industry is gaining traction with significant contracts, such as the sale of the Hongqi-9 air defense system and the export of submarines to Pakistan [4] - China Shipbuilding Defense announced a profit increase of 213.25% to 267.73% for the first half of the year, leading to a stock rise of nearly 8% [4] Consumer Market Activity - The new consumption sector is becoming active, with companies like Pop Mart seeing increased attention at recent toy exhibitions [5] - The liquor industry is also responding to market trends, with new product launches and stock price increases [5] Aviation Sector Developments - Cathay Pacific announced an $8.1 billion order for 14 Boeing 777-9 aircraft, marking its first deal with Boeing in 12 years, despite concerns over the safety record of Boeing aircraft [7] - The long delivery timeline for the 777-9 model raises potential issues regarding aircraft aging and maintenance [7] Energy Sector Updates - The State Grid reported record electricity usage due to high temperatures, with peak load reaching 1.233 billion kilowatts, an increase of 53 million kilowatts from last year [8] - Coal prices have risen significantly, impacting the steel industry, which is maintaining high production levels [8] Automotive Sector Performance - XPeng Motors reported a record monthly delivery of 36,717 vehicles in July, a year-on-year increase of 229.4% [10] - The company is expanding its presence in Europe, with significant sales growth and new model launches [11][12]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 先健科技公司 (在開曼群島註冊成立的有限公司) 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01302 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 40,000,000,000 | USD | 0.00000125 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 40,000,000,000 | USD | 0.00000125 | USD | | 50,000 | ...

Group 1: Market Performance - Hang Seng Index rose by 0.18%, gaining 45 points to close at 24,947 points; Hang Seng Tech Index increased by 0.03% [1] - Hong Kong stock market saw a morning trading volume of 120.6 billion HKD [1] Group 2: Notable Stock Movements - Coal stocks led the gains, with China Shenhua (01088) up 3.61% and Yanzhou Coal (01171) up 4.1%, as the fifth round of coking coal price hikes took effect [1] - Crystal International (02228) surged over 8% after signing a pipeline cooperation agreement with DoveTree, with a total order size of approximately 47 billion HKD and an initial payment of 51 million USD received [1] - Tsugami (01651) rose by 4.68% following a nearly 40% increase in Q1 net profit from its Japanese division and positive machine tool production data for June [1] - Xianjian Technology (01302) increased by 6.97%, with expectations of gradual price adjustments for related products in the second half of the year [1] - Pop Mart (09992) gained 6.31%, driven by strong demand for its proprietary IP, with Morgan Stanley highlighting its undervalued platform [1] - China Shipbuilding Defense (00317) rose over 7%, anticipating a more than double year-on-year increase in net profit for the first half of the year [1] - BYD Electronics (00285) increased by over 6%, benefiting from AI-driven growth in the liquid cooling market and entry into the Nvidia supply chain [1] - Wuling Motors (00305) surged over 10% after announcing a profit warning, with mid-term net profit soaring nearly threefold as the company actively expands in the new energy sector [1] Group 3: Declining Stocks - Qilu Expressway (01576) fell by 6.37% after issuing a profit warning, expecting a year-on-year decline of approximately 21.62% in mid-term net profit [2] - Dongfang Zhenxuan (01797) dropped over 7% amid public relations issues and the closure of Sam's Club member stores, despite its stock price doubling since early July [3] - Boya Interactive (00434) declined by over 6%, projecting a year-on-year profit decrease of 25% to 35% for the first half of the year [4]

Core Viewpoint - The article discusses the recent performance of Xianjian Technology (01302) and the impact of new pricing regulations on the medical device industry in China, particularly focusing on the aortic stent market and the expected recovery in the sector by 2025 [1] Group 1: Company Performance - Xianjian Technology's stock rose over 10%, currently trading at 2.2 HKD with a transaction volume of 214 million HKD [1] - The company is affected by new pricing regulations set by the National Healthcare Security Administration, which aims to reduce excessive markups in the supply chain [1] Group 2: Industry Insights - The price adjustments due to centralized procurement are expected to lead to a decline in the ex-factory prices of related products, impacting the company's revenue and profit in the second half of 2024 [1] - A one-year price adjustment period is anticipated to gradually clear by the second half of 2025, potentially reversing the current challenges faced by the company [1] - Citic Securities predicts that as policies ease and centralized procurement clears, many medical device companies will see performance and valuation recovery [1] - The medical device sector is expected to present increasing investment opportunities, particularly in international markets, with several companies projected to achieve high growth in international business by 2025 [1] - The strong performance of the Hong Kong medical device sector this year is likely to influence the A-share market, highlighting ongoing investment opportunities in both markets [1]

Core Viewpoint - The article discusses the recent performance of Xianjian Technology (01302) and the impact of new pricing regulations on the medical device industry in China, highlighting potential recovery and growth opportunities in the sector [1] Company Summary - Xianjian Technology's stock rose over 10%, currently trading at 2.2 HKD with a trading volume of 214 million HKD [1] - The company is affected by new pricing regulations from the National Healthcare Security Administration, which requires 12 domestic and foreign companies to re-evaluate the pricing of thoracic aortic stent products [1] - The price adjustments due to centralized procurement are expected to lead to a decline in the factory prices of related products, impacting the company's revenue and profit in the second half of 2024 [1] Industry Summary - The price adjustments are anticipated to clear up by the second half of 2025, potentially reversing the current challenges faced by the company [1] - Citic Securities indicates that as policies ease and centralized procurement clears, many medical device companies will see performance and valuation recovery [1] - The medical device sector is expected to present increasing investment opportunities, particularly from international business growth, with many companies projected to achieve high growth in international revenues by 2025 [1] - The strong performance of the Hong Kong medical device sector is likely to reflect positively on the A-share market, suggesting sustained investment opportunities in both markets [1]

8月6日，先健科技(01302)盘中上涨5.47%，截至09:30，报2.12元/股，成交517.86万元。 作者：行情君 截至2024年年报，先健科技营业总收入13.04亿元、净利润2.22亿元。 本文源自：金融界 先健科技专注于心脑血管和外周血管介入医疗器械的研发、生产及全球化发展，产品在国内市场占据领 先地位，并拓展至全球120多个国家和地区。公司已获得2,426项高质量专利，15款产品通过NMPA创新 医疗器械审查程序，持续推动技术突破与国际化发展。 ...

Core Viewpoint - The company is a leading player in the structural heart and peripheral intervention high-value consumables sector, with a diversified business model and strategic partnerships aimed at expanding its product offerings and market reach [1][2]. Group 1: Business Overview - The company operates under a "3+N" business layout, which includes three main product lines: structural heart disease, peripheral vascular intervention, and electrophysiology, along with multiple strategic cooperation projects [1]. - For the fiscal year 2024, the company reported a revenue of 1.304 billion yuan, reflecting a year-on-year growth of 2.88%, positioning it among the few high-value consumables firms in China with revenues exceeding 1 billion yuan [1]. - As of December 31, 2024, the company has established a robust patent portfolio with 2,426 patents and has received NMPA approval for 15 products under the "Special Review Procedure for Innovative Medical Devices" [1]. Group 2: Market Dynamics - In 2024, the National Healthcare Security Administration mandated 12 domestic and foreign companies, including the company, to revise the pricing of thoracic aortic stent products to enhance price transparency and reduce excessive markups [2]. - The price adjustments resulting from centralized procurement have led to a decline in the ex-factory prices of the company's related products, impacting revenue and profit in the second half of 2024 [2]. - The company is expected to see a recovery from these pricing challenges by the second half of 2025, as the market stabilizes [2]. Group 3: International Expansion and Product Development - The company has adopted a dual strategy of "innovation" and "internationalization," maintaining a leading market share in its primary products domestically [2]. - By the end of 2024, the company had established seven overseas subsidiaries and obtained 1,059 overseas registrations, with a sales network covering 117 countries and regions [2]. - The company anticipates that several second-generation aortic stent products will receive overseas registration approvals between 2025 and 2026, contributing to international revenue growth [2][3]. Group 4: Product Innovation - The company is pioneering iron-based absorbable stent technology, which addresses significant clinical challenges associated with existing biodegradable stents [3]. - The IBS Angle stent has received regulatory approvals in Malaysia and the EU, while the IBS Titan has been granted compassionate use approval in the U.S. [3]. - The company is progressing with its IBS drug-eluting coronary stent system, with clinical trials completed and applications submitted for NMPA and CE registration, expected to be approved by 2025-2026 [3]. Group 5: Financial Projections - Revenue projections for the company from 2025 to 2027 are estimated at 1.403 billion, 1.528 billion, and 1.736 billion yuan, representing year-on-year growth rates of 8%, 9%, and 14% respectively [3]. - The net profit attributable to the parent company is projected to reach 316 million, 388 million, and 526 million yuan for the same period, with growth rates of 42%, 23%, and 35% respectively [3].

Investment Rating - The investment rating for the company is "Buy" [1] Core Viewpoints - The company is a leading enterprise in the structural heart and peripheral intervention high-value consumables sector, with potential collaborations on multiple external BD projects. The main business is structured into three product lines and several strategic cooperation projects, aiming to expand its product portfolio [3][4] - The company is expected to see a reversal of difficulties as domestic price adjustments reach a bottom, with international business accelerating. The company has a strong market share in its main products and has established a significant international presence with 7 overseas subsidiaries and registrations in 1059 markets [4][5] - The iron-based stent platform is anticipated to disrupt the existing treatment landscape, with promising clinical results and regulatory approvals expected in the coming years [5][8] Summary by Sections Company Overview - The company focuses on structural heart disease and peripheral vascular disease, with a strong international sales network covering over 100 countries. It has a robust patent portfolio and is recognized as a leader in the domestic market [15][19] Financial Performance - The company achieved a revenue of 1.304 billion yuan in 2024, with a year-on-year growth of 2.88%. The projected revenues for 2025, 2026, and 2027 are expected to be 1.403 billion, 1.528 billion, and 1.736 billion yuan respectively, with growth rates of 8%, 9%, and 14% [8][10][29] Product Lines and Market Position - The company has a diversified product matrix, including structural heart disease devices and peripheral vascular solutions. The structural heart disease market in China is projected to grow significantly, with the company positioned to capture a substantial market share [31][34] - The company leads in the congenital heart disease occluder market, holding a 34% market share, and is well-positioned in the left atrial appendage occluder market, which is expected to grow rapidly [36][42] International Expansion - The company has accelerated its internationalization efforts, with overseas revenue accounting for approximately 26.6% of total revenue in 2024. The strategic partnership with Jianhu Medical is expected to enhance its presence in the electrophysiology field [29][30]